Clinical Oncology: Case Reports

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Rebecca Fitzpatrick Author

Rebecca_a_fitzpatrick@rush.edu

Subjects of specialization
cancer, cancer oncology, Carcinogenesis

Affiliation
Department of Internal Medicine, Division of Hematology, Oncology and Cell Therapy, Rush University Medical Center, Chicago, USA

Biography

Dr. Rebecca Fitzpatrick is working as scientist and professor at Department of Internal Medicine, Division of Hematology, Oncology and Cell Therapy, Rush University Medical Center, Chicago, USA . The author has specalization in cancer, cancer oncology, chemotherapy, Carcinogenesis, Chemotherapy

Publications

Case Report Open Access

Extreme Response to Immunotherapy in an Estrogen Receptor Positive Breast Cancer: A Case Report

Author(s):

Rebecca Fitzpatrick and Melody Cobleigh

Introduction: Currently, immune checkpoint inhibitors are not approved by the FDA for HR-positive breast cancer, although an extreme response was seen in the case below.

Case: The patient is a 72 year old, woman who was diagnosed in 1996, at age 48, with stage T2N2aM0, ER-positive infiltrating ductal cancer in her left breast. She completed 4 cycles of doxorubicin and cyclophosphamide and she received adjuvant tamoxifen, until 2004, then was switched to letrozole, which was completed in April, 2011, thus completing 15 years of endocrine treatment. She recurred in 2017 with pleomorphic invasive lobular carcinoma, ER 5%, PR 0%, and HER2 not amplified by FISH. She eventually progressed through 5 lines of treatment. The 2/2019 biopsy spec... view more»

Abstract HTML PDF

Google Scholars / Researchers Sites

Explore SciTechnol

GET THE APP